| Analyses of non-coding somatic drivers in 2,658 cancer whole genomes E Rheinbay, MM Nielsen, F Abascal, JA Wala, O Shapira, G Tiao, ... Nature 578 (7793), 102-111, 2020 | 627 | 2020 |
| Hacking the cancer genome: profiling therapeutically actionable long non-coding RNAs using CRISPR-Cas9 screening R Esposito, N Bosch, A Lanzós, T Polidori, C Pulido-Quetglas, R Johnson Cancer cell 35 (4), 545-557, 2019 | 197 | 2019 |
| Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis J Carlevaro-Fita, A Lanzós, L Feuerbach, C Hong, D Mas-Ponte, ... Communications Biology 3 (1), 1-16, 2020 | 196 | 2020 |
| Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features A Lanzós, J Carlevaro-Fita, L Mularoni, F Reverter, E Palumbo, R Guigó, ... Scientific Reports. 2017; 7: 41544, 2017 | 130 | 2017 |
| Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs A Vancura, A Lanzós, N Bosch-Guiteras, MT Esteban, AH Gutierrez, ... NAR Cancer 3 (2), zcab013, 2021 | 27 | 2021 |
| Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities R Esposito, T Polidori, DF Meise, C Pulido-Quetglas, P Chouvardas, ... Cell genomics 2 (9), 2022 | 20 | 2022 |
| Tumour mutations in long noncoding RNAs enhance cell fitness R Esposito, A Lanzós, T Uroda, S Ramnarayanan, I Büchi, T Polidori, ... Nature communications 14 (1), 3342, 2023 | 10 | 2023 |
| EACR Cancer Genomics 2019 conference: from tumour evolution to personalised immunotherapy A Lanzós, K Elliott The FEBS journal, 2019 | 1 | 2019 |
| Identifying novel biomarkers with deep proteomics profiling and survival analysis in NSCLC patients treated with anti-PD-1-blockade E Nguyen, R Poli, K Sklodowski, V Dozio, A Lanzós, K Beeler, E Romano Annals of Oncology 32, S1382, 2021 | | 2021 |
| Big Proteomic Data from a Digital Biobank Boost the Confidence in Biomarker Discovery A Lanzós, R Bruderer, J Muntel, L Reiter, O Rinner, S Schegk ASMS 2021, 2021 | | 2021 |
| Immune-related adverse effects (irAEs) associated proteomic profile in late-stage NSCLC patients after PD-1 blockade K Sklodowski, V Dozio, R Poli, A Lanzós, S Lopez-Lastra, K Beeler, ... Cancer Research 81 (13_Supplement), 1615-1615, 2021 | | 2021 |
| Protein signature associated with response and progression free survival in late-stage NSCLC patients treated with anti-PD-1 blockade E Romano, K Sklodowski, V Dozio, A Lanzós, K Beeler Annals of Oncology 32, S12, 2021 | | 2021 |
| Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients K Sklodowski, V Dozio, S Lopez-Lastra, A Lanzós, K Beeler, E Romano Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| Bioinformatic Analysis of Cancer Driver Long Non-coding RNAs AAL Camaioni Faculty of Medicine of the University of Bern, 2019 | | 2019 |
Rory JohnsonUniversity College DublinE-mailová adresa ověřena na: ucd.ie